Zepbound (Tirzepatide) in Adults 65 and Older: What Geriatric Patients and Prescribers Need to Know

Is Zepbound Approved for Use in Adults Over 65?

Zepbound carries no upper age cutoff in its FDA labeling. The prescribing information states that no dose adjustment is required based on age alone, and pharmacokinetic studies showed no clinically significant differences in tirzepatide exposure between adults younger than 65 and those 65 or older. [1]

The SURMOUNT clinical program enrolled relatively small proportions of older adults. SURMOUNT-1 (N=2,539) enrolled participants with a mean age of 44.9 years, and fewer than 15% of participants were 65 or older across the four SURMOUNT trials. [2] This means the evidence base specifically for older adults is thinner than for middle-aged populations, and the clinical picture requires extrapolation, careful subgroup review, and individualized judgment.

What the FDA Label Actually Says

The Zepbound prescribing information includes a section on use in specific populations. For geriatric use, it reads: "No dose adjustment is required based on age. Tirzepatide exposure was similar in participants 65 years and older compared to younger adults." [1] The label does not restrict use in this age group, nor does it require a modified titration schedule.

The absence of a dose restriction is not a green light to ignore age-related physiology. Reduced renal clearance, lower baseline muscle mass, polypharmacy burden, and altered GI motility are all common in patients over 65, and each one affects how tirzepatide behaves clinically.

Regulatory Context for "Off-Label" Framing

Because Zepbound is approved for adults with obesity or overweight plus comorbidities, prescribing it to a 68-year-old with a BMI of 31 and hypertension is on-label by every standard definition. The "off-label" framing sometimes applied to geriatric use reflects the underrepresentation of older adults in trials, not a regulatory restriction. Clinicians should understand this distinction before counseling patients.

Efficacy Data in Older Adults: What the SURMOUNT Trials Show

The best available data for tirzepatide in adults 65 and older comes from subgroup analyses of SURMOUNT-1 and SURMOUNT-2, plus the SURMOUNT-OSA trial, which enrolled adults with obesity and obstructive sleep apnea, a condition whose prevalence rises sharply after age 60. [3]

SURMOUNT-1 Subgroup

In SURMOUNT-1, all three active doses of tirzepatide (5 mg, 10 mg, 15 mg) outperformed placebo for weight loss at 72 weeks. [2] The headline result for the 15 mg dose was 20.9% mean body weight reduction. Post-hoc analyses stratified by age showed that participants 65 and older achieved statistically significant and clinically meaningful weight loss, though the absolute percentage was modestly lower than the overall cohort. The interaction p-value for age as a subgroup modifier was not significant, meaning age alone did not substantially change treatment response. [2]

SURMOUNT-4 and Weight Regain Risk

SURMOUNT-4 (N=783) examined what happens when tirzepatide is discontinued after 36 weeks of treatment. Participants who switched to placebo regained approximately 14% of body weight over the following 52 weeks, while those who continued on 15 mg maintained their loss and lost an additional 5.5%. [4] For older adults, this weight regain trajectory is a particular concern because repeated cycles of weight loss and regain accelerate lean mass depletion over time.

SURMOUNT-OSA Signal

SURMOUNT-OSA enrolled adults aged 18 to 75 with obesity and moderate-to-severe obstructive sleep apnea. Mean participant age was approximately 50 years. Tirzepatide reduced the apnea-hypopnea index (AHI) by 27.4 events per hour versus placebo at 52 weeks (P<0.001), alongside 18.1% weight reduction. [3] Sleep apnea burden is disproportionately high in adults over 65, making this trial especially relevant for the geriatric prescriber.

The Sarcopenia Problem: Why Muscle Loss Matters More After 65

Older adults lose skeletal muscle mass at a rate of roughly 1 to 2% per year after age 50, a process called sarcopenia. Any weight-loss intervention that does not actively preserve lean mass can accelerate functional decline, increase fall risk, and worsen frailty in this population. [5]

GLP-1 receptor agonists, including tirzepatide, cause weight loss through a combination of fat mass reduction and lean mass reduction. A 2023 meta-analysis in Obesity Reviews (12 RCTs, N=3,801) found that GLP-1 class agents reduced lean body mass by an average of 1.2 kg, and lean mass loss accounted for 25 to 39% of total weight lost depending on the agent and duration. [6]

Does Resistance Exercise Close the Gap?

The current evidence suggests yes, at least partially. A 2024 study published in JAMA Network Open (N=272) found that combining semaglutide 2.4 mg with a structured resistance training program preserved lean mass significantly better than semaglutide alone at 44 weeks. Lean mass loss in the exercise group was 0.8 kg versus 2.1 kg in the medication-only group. [7] Tirzepatide-specific resistance exercise data in older adults is still accumulating, but the biological rationale transfers directly.

Protein Intake as a Mitigation Strategy

The current Recommended Dietary Allowance for protein is 0.8 g/kg/day, a target most older adults on GLP-1 therapy will not meet given the appetite suppression these drugs produce. Some geriatric nutrition guidelines recommend 1.2 to 1.6 g/kg/day for older adults in catabolic states, which includes active weight loss. [8] Prescribers initiating Zepbound in patients 65 and older should connect them with a registered dietitian before or within the first month of therapy.

Screening for Sarcopenia Before Starting

The SARC-F questionnaire is a validated, five-item tool for identifying sarcopenia risk in clinical settings. [9] A score of 4 or higher out of 10 signals elevated risk. Patients who screen positive may warrant DEXA body composition scanning at baseline and at six months to quantify lean mass changes objectively. This is not a standard-of-care requirement in the FDA label, but it represents reasonable clinical practice when initiating a weight-loss drug in a 70-year-old with limited functional reserve.

Safety Considerations Specific to the 65+ Age Group

Gastrointestinal Adverse Events

Nausea, vomiting, diarrhea, and constipation are the most common adverse effects of tirzepatide across all age groups. In SURMOUNT-1, gastrointestinal adverse events led to discontinuation in 4.3% of participants on the 15 mg dose versus 0.8% on placebo. [2] Older adults are at higher risk for dehydration from these events because of reduced thirst sensation, lower total body water, and more frequent baseline use of diuretics or ACE inhibitors that sensitize the kidneys to volume depletion. Prescribers should counsel patients over 65 to increase fluid intake proactively during titration and should check renal function and electrolytes within 4 to 6 weeks of each dose increase.

Hypoglycemia and Diabetes Overlap

Tirzepatide is also FDA-approved as Mounjaro for type 2 diabetes management. Many patients over 65 who would qualify for Zepbound also have type 2 diabetes or prediabetes. When tirzepatide is added to existing sulfonylurea or insulin therapy, hypoglycemia risk rises substantially. The SURPASS-2 trial (N=1,879) reported symptomatic hypoglycemia in 18.9% of patients on tirzepatide 15 mg plus insulin glargine at 40 weeks. [10] For older adults, hypoglycemia carries added danger because it increases fall risk and is a leading cause of emergency department visits in people over 65.

Fall Risk and Orthostatic Hypotension

Rapid weight loss can worsen orthostatic hypotension, especially in patients taking antihypertensives. As body weight drops, existing blood pressure medications may become relatively overdosed. A systematic review in the Journal of the American Geriatrics Society found that GLP-1 receptor agonist use was associated with an 18% lower rate of cardiovascular events but did not specifically quantify fall incidence in older adults. [11] Clinicians should reassess antihypertensive doses within the first 8 to 12 weeks of tirzepatide therapy in patients over 65 who are on three or more antihypertensives.

Renal Function Monitoring

Volume depletion from GI adverse events can cause acute kidney injury in patients with pre-existing chronic kidney disease, which affects approximately 38% of adults over 65 in the United States. [12] The Zepbound prescribing information does not require dose adjustment for renal impairment, but prescribers should use clinical judgment when initiating in patients with an eGFR below 30 mL/min/1.73m² and should hold the dose during acute illness involving significant fluid losses.

Dosing Tirzepatide in Patients 65 and Older

The standard titration schedule for Zepbound starts at 2.5 mg subcutaneously once weekly for four weeks, then escalates by 2.5 mg every four weeks as tolerated, targeting a maintenance dose of 5 mg, 10 mg, or 15 mg weekly. [1] For older adults, the prescribing information does not mandate a modified schedule, but clinical practice often supports a slower titration, spending 6 to 8 weeks at each intermediate dose rather than 4 weeks.

When to Pause Titration

Dose escalation should be paused in any patient experiencing significant nausea, vomiting more than twice weekly, diarrhea more than three times daily, or unintentional weight loss exceeding 2% of body weight per month. For a 75-year-old weighing 80 kg, a 2% monthly loss equates to 1.6 kg per month. Rapid weight loss at this pace in older adults raises the probability that lean mass loss is disproportionate.

Maximum Dose Considerations

The approved maximum dose is 15 mg weekly. Older adults with lower baseline BMI values (27 to 31 kg/m²) and significant frailty may achieve adequate clinical benefit at 5 mg or 10 mg, avoiding the higher GI adverse event rates seen at 15 mg. The clinically meaningful weight loss threshold for cardiometabolic benefit is generally considered to be 5 to 10% of body weight, a target achievable at lower doses for many patients.

Cardiovascular Benefits in Older Adults

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over 39.8 months in adults with established cardiovascular disease and obesity but without diabetes. [13] Mean participant age was 61.6 years, and the trial included a substantial proportion of adults over 65. A tirzepatide-specific cardiovascular outcomes trial, SURMOUNT-MMO, is ongoing and expected to report around 2027. Until those data are available, cardiovascular risk reduction with tirzepatide in older adults is supported primarily by extrapolation from the GLP-1 class data and from metabolic improvements seen in SURMOUNT subgroup analyses.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "In patients with obesity and established cardiovascular disease, GLP-1 receptor agonist therapy with proven cardiovascular benefit is recommended over other weight-loss medications." [14] This guidance applies to older adults with obesity and prior MI, stroke, or peripheral artery disease.

Polypharmacy and Drug Interactions

Adults over 65 take an average of 5.6 prescription medications simultaneously. Tirzepatide slows gastric emptying, which delays the absorption of oral co-administered drugs. [1] This effect is most clinically relevant for:

• Levothyroxine: absorption reduced by delayed gastric emptying; take on an empty stomach at least 30 minutes before the tirzepatide injection day and separate timing when possible.
• Warfarin: INR may become less stable during active dose titration; increase INR monitoring frequency to every two weeks during the first three months.
• Oral contraceptives: relevant for peri-menopausal patients 60 to 64; recommend barrier contraception during GI-heavy titration periods.
• Metformin and SGLT2 inhibitors: volume depletion risk compounds when these are combined with tirzepatide in patients experiencing GI side effects.

Practical Clinical Checklist for Starting Zepbound in a Patient Over 65

Before writing the prescription, a geriatric-aware clinician should confirm or complete each of the following:

1. Confirm BMI threshold eligibility (30+ or 27+ with comorbidity).
2. Screen for personal or family history of medullary thyroid carcinoma or MEN2 syndrome (absolute contraindication). [1]
3. Administer SARC-F questionnaire; consider baseline DEXA if score is 4 or higher.
4. Review full medication list for delayed-absorption interactions.
5. Check baseline renal function (serum creatinine, eGFR), electrolytes, fasting glucose, and HbA1c.
6. Assess fall risk using the Timed Up and Go (TUG) test or equivalent.
7. Refer to registered dietitian for high-protein meal planning targeting 1.2 g/kg/day or higher.
8. Prescribe or refer to a resistance exercise program (2 to 3 sessions per week, targeting major muscle groups).
9. Counsel patient and caregiver on dehydration recognition and when to hold the dose (persistent vomiting, fever, inability to tolerate fluids).
10. Schedule 4-week follow-up after first injection, then monthly through dose titration.

What Patients Over 65 Should Ask Their Prescriber

Older adults considering Zepbound often have reasonable concerns that go beyond what standard prescribing visits cover. Patients who ask specific questions tend to have better outcomes because individualized counseling gets built into the plan earlier.

Questions worth raising at the initial visit include: What is my current muscle mass, and will we track it? How will we adjust my blood pressure medications as I lose weight? What protein intake target should I hit each day? Are any of my current medications likely to be absorbed differently on tirzepatide? What side effects should make me call before my next scheduled visit?

The American Geriatrics Society's "Beers Criteria" does not list GLP-1 receptor agonists as potentially inappropriate medications in older adults. [15] This absence is meaningful: the expert panel reviewed the drug class and determined the evidence did not support a general caution for the geriatric population as a whole.